Asbrip

Asbrip is a molecularly activated dietary supplement developed by Catalysis S.L. intended to support respiratory health. It contains a combination of antioxidants and plant extracts, including ascorbic acid, malic acid, fumaric acid, eucalyptus oil, and menthol. The product is marketed for both human and veterinary use (as Asbrip Pets) to alleviate symptoms of respiratory infections such as cough and congestion. In the context of the COVID-19 pandemic, Asbrip has been evaluated in clinical trials, frequently in combination with the immunomodulatory supplement Viusid, to assess its efficacy in reducing the severity of mild to moderate respiratory symptoms associated with SARS-CoV-2 infection. The manufacturer utilizes a proprietary "molecular activation" process claimed to enhance the biological activity of the ingredients.

Brand names

AsbripAsbrip Pets

Other names

Asbrip oral solution